114 related articles for article (PubMed ID: 2979265)
41. The effect of omeprazole on gastric acidity and the absorption of liver cobalamins.
Kittang E; Aadland E; Schjønsby H; Røhss K
Scand J Gastroenterol; 1987 Mar; 22(2):156-60. PubMed ID: 3576126
[TBL] [Abstract][Full Text] [Related]
42. Omeprozole therapy in pediatric patients after liver and intestinal transplantation.
Kaufman SS; Lyden ER; Brown CR; Davis CK; Andersen DA; Olsen KM; Bergman KL; Horslen SP; Sudan DL; Fox IJ; Shaw BW; Langnas AN
J Pediatr Gastroenterol Nutr; 2002 Feb; 34(2):194-8. PubMed ID: 11840039
[TBL] [Abstract][Full Text] [Related]
43. Omeprazole inhibits nocturnal and pentagastrin-stimulated gastric secretion in man.
Wilson JA; Boyd EJ; Wormsley KG
Dig Dis Sci; 1984 Sep; 29(9):797-801. PubMed ID: 6432499
[TBL] [Abstract][Full Text] [Related]
44. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.
Sharma BK; Walt RP; Pounder RE; Gomes MD; Wood EC; Logan LH
Gut; 1984 Sep; 25(9):957-64. PubMed ID: 6469081
[TBL] [Abstract][Full Text] [Related]
45. Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole.
Prewett EJ; Hudson M; Nwokolo CU; Sawyerr AM; Pounder RE
Gastroenterology; 1991 Apr; 100(4):873-7. PubMed ID: 2001826
[TBL] [Abstract][Full Text] [Related]
46. Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib.
Scott G; Vinluan Reynolds C; Milosavljev S; Langholff W; Shenouda M; Rordorf C
Clin Pharmacokinet; 2004; 43(5):341-8. PubMed ID: 15080766
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients.
Thomson AB; Kirdeikis P; Lastiwka R; Röhss K; Sinclair P; Olofsson B
Can J Gastroenterol; 1997; 11(8):657-60. PubMed ID: 9459044
[TBL] [Abstract][Full Text] [Related]
48. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects.
Hassan-Alin M; Andersson T; Niazi M; Röhss K
Eur J Clin Pharmacol; 2005 Jan; 60(11):779-84. PubMed ID: 15578172
[TBL] [Abstract][Full Text] [Related]
49. The effect of 20 Mg omeprazole daily on serum gastrin, 24-h intragastric acidity, and bile acid concentration in duodenal ulcer patients.
Naesdal J; Bankel M; Bodemar G; Gotthard R; Lundquist G; Walan A
Scand J Gastroenterol; 1987 Jan; 22(1):5-12. PubMed ID: 3551048
[TBL] [Abstract][Full Text] [Related]
50. Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration.
Chiverton SG; Howden CW; Burget DW; Hunt RH
Aliment Pharmacol Ther; 1992 Feb; 6(1):103-11. PubMed ID: 1543812
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis.
Andersson T; Olsson R; Regårdh CG; Skånberg I
Clin Pharmacokinet; 1993 Jan; 24(1):71-8. PubMed ID: 8448974
[TBL] [Abstract][Full Text] [Related]
52. Effects of single intravenously administered doses of omeprazole and ranitidine on intragastric pH and plasma gastrin concentration in nonfed ponies.
Baker SJ; Gerring EL
Am J Vet Res; 1993 Dec; 54(12):2068-74. PubMed ID: 8116940
[TBL] [Abstract][Full Text] [Related]
53. Effect of intermittent weekend therapy with omeprazole on basal and bombesin- and pentagastrin-stimulated gastric acid and serum gastrin.
Crobach LF; Jansen JB; Lamers CB
Scand J Gastroenterol; 1988 May; 23(4):407-12. PubMed ID: 3381063
[TBL] [Abstract][Full Text] [Related]
54. Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
[TBL] [Abstract][Full Text] [Related]
55. Fade and tachyphylaxis of gastric acid secretory response to pentagastrin in rat isolated gastric mucosa.
Hirst BH; Holland J; Parsons ME; Price CA
Br J Pharmacol; 1988 Dec; 95(4):1047-56. PubMed ID: 3219480
[TBL] [Abstract][Full Text] [Related]
56. Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure.
Howden CW; Payton CD; Meredith PA; Hughes DM; Macdougall AI; Reid JL; Forrest JA
Eur J Clin Pharmacol; 1985; 28(6):637-40. PubMed ID: 4065187
[TBL] [Abstract][Full Text] [Related]
57. The pharmacokinetic responses of humans to 20 g of alanyl-glutamine dipeptide differ with the dosing protocol but not with gastric acidity or in patients with acute Dengue fever.
Klassen P; Mazariegos M; Solomons NW; Fürst P
J Nutr; 2000 Feb; 130(2):177-82. PubMed ID: 10720166
[TBL] [Abstract][Full Text] [Related]
58. Time course of inhibition of gastric acid secretion by omeprazole and ranitidine in gastric fistula rats.
Seensalu R; Girma K; Romell B; Nilsson G
Eur J Pharmacol; 1990 May; 180(1):145-52. PubMed ID: 2364999
[TBL] [Abstract][Full Text] [Related]
59. Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects.
Small DS; Royalty J; Cannady EA; Hale C; Wang MD; Downs D; Suico JG
Pharmacotherapy; 2016 Jul; 36(7):749-56. PubMed ID: 27284735
[TBL] [Abstract][Full Text] [Related]
60. Antisecretory effect and oral pharmacokinetics following low dose omeprazole in man.
Howden CW; Forrest JA; Meredith PA; Reid JL
Br J Clin Pharmacol; 1985 Aug; 20(2):137-9. PubMed ID: 3929808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
